News
CPHRF
11.77
0.00%
0.00
Weekly Report: what happened at CPHRF last week (0615-0619)?
Weekly Report · 4d ago
Cipher Pharma shareholders approve director slate at annual meeting
PUBT · 06/18 17:19
Weekly Report: what happened at CPHRF last week (0608-0612)?
Weekly Report · 06/15 09:29
Weekly Report: what happened at CPHRF last week (0601-0605)?
Weekly Report · 06/08 09:27
Weekly Report: what happened at CPHRF last week (0525-0529)?
Weekly Report · 06/01 09:29
Weekly Report: what happened at CPHRF last week (0518-0522)?
Weekly Report · 05/25 09:30
Weekly Report: what happened at CPHRF last week (0511-0515)?
Weekly Report · 05/18 09:30
Cipher Pharmaceuticals price target raised to C$22 from C$21 at Stifel
TipRanks · 05/13 18:07
CANADA RESEARCH ROUNDUP-Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Reuters · 05/12 10:30
CIPHER PHARMACEUTICALS INC <CPH.TO>: CANACCORD GENUITY RESUMES COVERAGE WITH HOLD RATING; TARGET PRICE C$17
Reuters · 05/12 03:25
Stifel Nicolaus Remains a Buy on Cipher Pharmaceuticals (CPHRF)
TipRanks · 05/11 13:28
Weekly Report: what happened at CPHRF last week (0504-0508)?
Weekly Report · 05/11 09:29
Cipher Q1 FY26 net income more than doubles to $6.2 million; revenue rises 4% to $12.5 million
PUBT · 05/07 22:02
Cipher Pharmaceuticals GAAP EPS of $0.24 beats by $0.10, revenue of $12.51M beats by $0.31M
Seeking Alpha · 05/07 21:52
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Reuters · 05/07 21:19
BRIEF-Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million
Reuters · 05/07 21:00
CIPHER PHARMACEUTICALS REPORTS FIRST QUARTER RESULTS
Reuters · 05/07 21:00
Weekly Report: what happened at CPHRF last week (0427-0501)?
Weekly Report · 05/04 09:28
Cipher Pharmaceuticals launches share buyback of up to 1.49M shares
Seeking Alpha · 05/01 12:40
Cipher Pharma launches NCIB to buy back up to 1,490,343 shares
PUBT · 05/01 11:05
More
Webull provides a variety of real-time CPHRF stock news. You can receive the latest news about Cipher Phrmctcls through multiple platforms. This information may help you make smarter investment decisions.
About CPHRF
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.